Last checked at 11 Jun 2013 16:19

For immediate release | 11 June 2013 |
Â
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Â
Exercise of Options and Director's Dealings
Â
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that the Company was notified on 11 June 2013 that Richard Wright, a Director of the Company, exercised options to acquire 649,376 ordinary shares of 1 pence each (Ordinary Shares) at a price of 8.5p per share and 113,000 Ordinary Shares at 7.75 pence per share, all 762,376 of which were subsequently sold on 11 June 2013 at 36.5p pence per share. Following these transactions, Mr Wright holds 190,768 Ordinary Shares in the Company, representing approximately 0.08% of the enlarged issued share capital.
Â
Application has been made for the 762,376 Ordinary Shares to be admitted to AIM, with trading expected to commence on 17 June 2013 ("Admission"). Upon Admission the shares will rank pari passu in all respects with the existing Ordinary Shares of the Company.
Â
After Admission, Alliance will have 249,817,643 Ordinary Shares in issue.
Â
Â
For further information:
Â
Alliance Pharma plc | + 44 (0) 1249 466966 | |
John Dawson, Chief Executive | ||
Richard Wright, Finance Director | ||
www.alliancepharma.co.uk | ||
Buchanan | + 44 (0) 20 7466 5000 | |
Mark Court / Fiona Henson / Sophie Cowles www.buchanan.uk.com | ||
Numis Securities Limited | + 44 (0) 20 7260 1000 | |
Nominated Adviser: Michael Meade / Oliver Cardigan / Freddie Barnfield | ||
Corporate Broking: David Poutney | ||
Â
Notes to editors:
Â
About Alliance
Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.
Â
Â
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
Â